TriangleSeneca Valley Virus-001 (SVV-001) (NCT06889493)
Seneca Valley Virus-001 (SVV-001) trial for Neuroendocrine Carcinoma (NCT06889493). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for advanced neuroendocrine cancers that have progressed on at least one line of therapy, in adults: poorly differentiated neuroendocrine carcinoma, or grade 3 well differentiated neuroendocrine tumors.
The idea: add an oncolytic virus, SVV 001, to the immunotherapies nivolumab and ipilimumab. Groups receive a single dose or multiple doses of the virus, to find the highest dose and frequency that patients tolerate. Seneca Therapeutics is listed as a collaborator.
This phase 1 trial plans 36 patients. At the University of Miami, Peter Hosein leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.